BRIEF-Ipsen partner Exelixis obtains FDA approval of CABOMETYX tablets

* Announces that its partner Exelixis obtained FDA approval of CABOMETYX (cabozantinib) tablets for patients with advanced renal cell carcinoma who have received prior anti-angiogenic therapy Source text for Eikon: Further company coverage: (Gdynia Newsroom)